1. Home
  2. EPM vs TLSA Comparison

EPM vs TLSA Comparison

Compare EPM & TLSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Evolution Petroleum Corporation Inc.

EPM

Evolution Petroleum Corporation Inc.

SELL

Current Price

$3.71

Market Cap

143.0M

Sector

Energy

ML Signal

SELL

Logo Tiziana Life Sciences Ltd.

TLSA

Tiziana Life Sciences Ltd.

SELL

Current Price

$1.05

Market Cap

145.1M

Sector

Health Care

ML Signal

SELL

Company Overview

Basic Information
Metric
EPM
TLSA
Founded
2003
2013
Country
United States
United Kingdom
Employees
N/A
N/A
Industry
Oil & Gas Production
Biotechnology: Pharmaceutical Preparations
Sector
Energy
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
143.0M
145.1M
IPO Year
1996
2017

Fundamental Metrics

Financial Performance
Metric
EPM
TLSA
Price
$3.71
$1.05
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
4
2
Target Price
$4.94
★ $8.02
AVG Volume (30 Days)
396.5K
★ 674.2K
Earning Date
11-05-2026
05-01-2026
Dividend Yield
★ 13.08%
N/A
EPS Growth
N/A
★ N/A
EPS
N/A
★ N/A
Revenue
★ $43,229,621.00
N/A
Revenue This Year
$3.66
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
★ N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$3.19
$0.76
52 Week High
$4.99
$2.10

Technical Indicators

Market Signals
Indicator
EPM
TLSA
Relative Strength Index (RSI) 52.57 51.06
Support Level $3.46 $0.90
Resistance Level $3.78 $1.21
Average True Range (ATR) 0.09 0.09
MACD 0.01 -0.00
Stochastic Oscillator 71.25 39.90

Price Performance

Historical Comparison
EPM
TLSA

About EPM Evolution Petroleum Corporation Inc.

Evolution Petroleum Corp is an independent energy company focused on owning and investing in onshore oil and natural gas properties across the United States. Its portfolio includes non-operated interests in various production fields such as CO2 enhanced oil recovery in Louisiana, secondary recovery production in Wyoming, and shale gas reservoirs in Texas and North Dakota. The company generates revenue from the production and sale of oil and natural gas, leveraging specialized technologies to extend reservoir life and enhance recoveries.

About TLSA Tiziana Life Sciences Ltd.

Tiziana Life Sciences Ltd is a clinical-stage biotechnology company that specializes in developing transformative therapies for neurodegenerative and neuroinflammatory diseases. The company's clinical pipeline includes drug assets for Non-Active Secondary Progressive Multiple Sclerosis, Multiple System Atrophy, Alzheimer's, and Amyotrophic Lateral Sclerosis. The company's mission is to design and deliver next-generation immunotherapies for neurodegenerative and neuroinflammatory diseases. The company's main immunotherapeutic candidate, Foralumab (TZLS-401), is being developed for Non-Active Secondary Progressive Multiple Sclerosis, Alzheimer's, and other CNS indications.

Share on Social Networks: